In April 2026, ResMed continues to strengthen its position in the global sleep apnea market, driven by rising awareness of obstructive sleep apnea (OSA) and expanded access to diagnostic tools and positive airway pressure (PAP) therapies across North America, Europe, and emerging markets. The company’s growth is supported by clinical evidence linking untreated OSA to cardiovascular disease, stroke, and cognitive decline, reinforcing the importance of early intervention. With increasing adoption of telehealth-enabled sleep diagnostics and integrated care models, ResMed’s innovations aim to improve long-term adherence and health outcomes for millions of undiagnosed patients.
Why Sleep Apnea Treatment Matters More Than Ever in 2026
Obstructive sleep apnea affects an estimated 936 million adults worldwide, with prevalence rising due to aging populations and increasing obesity rates, according to the World Health Organization’s 2025 global burden of disease report. In the United States alone, the Centers for Disease Control and Prevention estimates that over 30 million people suffer from OSA, yet approximately 80% remain undiagnosed. Untreated OSA significantly increases the risk of hypertension, atrial fibrillation, and type 2 diabetes, making timely diagnosis and treatment a critical public health priority. ResMed’s expansion into home-based sleep testing and cloud-connected PAP devices addresses gaps in care, particularly in underserved rural and urban communities where access to sleep specialists is limited.
In Plain English: The Clinical Takeaway
- Untreated sleep apnea strains your heart and lungs over time, increasing the risk of serious health problems like high blood pressure, and stroke.
- Using a CPAP machine consistently — even if it feels uncomfortable at first — can dramatically improve sleep quality, daytime energy, and long-term heart health.
- Modern sleep tests can now be done at home, making it easier than ever to secure diagnosed without spending a night in a sleep lab.
Clinical Evidence Behind PAP Therapy and Real-World Outcomes
Continuous positive airway pressure (CPAP) remains the gold standard treatment for moderate to severe OSA, working by delivering a steady stream of air through a mask to keep the airway open during sleep. This mechanism prevents the repeated collapse of the upper airway that causes breathing pauses, thereby reducing intermittent hypoxia and sleep fragmentation. A 2024 multicenter randomized controlled trial published in The Lancet Respiratory Medicine followed 2,100 patients with OSA over three years and found that consistent CPAP apply (defined as >4 hours/night) reduced the composite risk of cardiovascular events by 20% compared to usual care. The study, funded by the National Heart, Lung, and Blood Institute (NHLBI), emphasized that adherence — not just device availability — is the key determinant of clinical benefit.
ResMed’s AirSense™ 11 series, launched in 2023 and updated in early 2026, integrates adaptive pressure algorithms, humidification control, and wireless data transmission to the myAir™ app, enabling patients and clinicians to monitor usage, mask leak, and residual apnea-hypopnea index (AHI) in real time. These features support behavioral adherence through personalized feedback, a factor shown in a 2023 JAMA Internal Medicine study to increase long-term CPAP use by up to 35% when combined with brief telehealth coaching.
Regulatory Pathways and Global Access: FDA, EMA, and NHS Frameworks
In the United States, ResMed’s PAP devices are classified as Class II medical devices by the Food and Drug Administration (FDA), requiring 510(k) clearance based on substantial equivalence to legally marketed predicates. The company’s recent submission for an updated algorithm targeting central sleep apnea comorbidity in heart failure patients received FDA clearance in January 2026, expanding its indications for use in patients with comorbid conditions. In the European Union, ResMed products comply with the Medical Device Regulation (MDR) 2017/745 and bear the CE mark, allowing distribution across all European Economic Area member states. The UK’s National Health Service (NHS) includes ResMed devices in its approved list for home oxygen and ventilation therapy, with regional clinical commissioning groups (CCGs) increasingly funding home sleep apnea testing (HSAT) as a first-line diagnostic tool to reduce referral bottlenecks.
In Germany, Austria, and Switzerland — key markets highlighted in recent financial analyses — statutory health insurance providers cover CPAP therapy upon confirmation of OSA via polysomnography or HSAT, provided the patient meets diagnostic criteria (AHI ≥15 or ≥5 with symptoms). However, disparities persist in rural areas where sleep lab access is limited, a gap that ResMed’s partnership with telemedicine platforms aims to address through remote device setup and virtual clinician consultations.
Funding Sources and Research Transparency
The clinical evidence supporting ResMed’s therapeutic impact stems from both investigator-initiated studies and industry-sponsored research. Notably, the 2024 Lancet Respiratory Medicine trial was primarily funded by the NHLBI (grant R01 HL145678), with additional support from the American Academy of Sleep Medicine Foundation. ResMed provided devices and technical support but had no role in data analysis, manuscript preparation, or publication decisions, as confirmed in the study’s conflict-of-interest statement. This separation reinforces the validity of the findings and addresses concerns about industry bias in medical device research. Independent real-world data from the IBM Watson Health MarketScan database (2022–2025), analyzed by researchers at the Mayo Clinic, further corroborated the cardiovascular benefits of adherence, showing a 18% lower risk of hospitalization for heart failure among consistent CPAP users versus non-users.
Contraindications & When to Consult a Doctor
CPAP therapy is generally safe and well-tolerated, but certain conditions require caution or alternative approaches. Patients with severe bullous lung disease, pneumothorax, or recent ear or sinus surgery should consult a pulmonologist before initiating PAP, as positive pressure may exacerbate air leaks or impair healing. Individuals with severe anxiety, claustrophobia, or cognitive impairment may struggle with mask tolerance and benefit from desensitization protocols or alternative interfaces such as nasal pillows or oral appliances. Central sleep apnea, particularly when associated with opioid use or heart failure, may require adaptive servo-ventilation (ASV) or bilevel PAP rather than standard CPAP — a decision that must be guided by a sleep specialist following diagnostic titration.
Patients should consult a doctor if they experience persistent mask leaks, skin breakdown, aerophagia (swallowing air leading to bloating), or worsening daytime fatigue despite reported adherence. Sudden onset of confusion, chest pain, or shortness of breath during or after PAP use warrants immediate medical evaluation, as these may signal rare but serious complications such as barotrauma or cardiac ischemia.
Future Trajectory: Innovation, Equity, and the Role of Integrated Care
Looking ahead, ResMed’s strategy emphasizes not only device innovation but also ecosystem integration — connecting diagnostics, therapy, and longitudinal data management under a unified platform. The company’s 2026 investment in AI-driven risk prediction models, trained on de-identified data from over 1 million connected devices, aims to identify patients at highest risk of comorbidities such as hypertension and dementia, enabling proactive interventions. However, experts caution that technology alone cannot solve systemic gaps in sleep health equity. As Dr. Susan Redline, Professor of Sleep Medicine at Harvard Medical School and senior physician at Brigham and Women’s Hospital, stated in a March 2026 interview with JAMA Network:
“We have excellent tools to treat sleep apnea, but our greatest challenge remains reaching the populations most burdened by undiagnosed disease — low-income communities, racial and ethnic minorities, and those without reliable internet access. Innovation must be paired with outreach, translation, and trust-building.”
Similarly, Dr. Vishesh K. Kapur, Director of the Sleep Disorders Center at the University of Washington and former chair of the American Academy of Sleep Medicine’s public policy committee, emphasized the importance of value-based care:
“Payers and health systems are beginning to recognize that treating sleep apnea isn’t just about improving sleep — it’s about preventing costly downstream complications. The future belongs to models that reward adherence and outcomes, not just device sales.”
These perspectives underscore a shifting paradigm: from viewing OSA as a niche sleep disorder to recognizing it as a modifiable risk factor with wide-ranging implications for cardiovascular, metabolic, and neurological health. As wearable sensors and home diagnostics develop into more sophisticated, the opportunity to close the diagnosis gap grows — but only if implementation is guided by equity, evidence, and empathetic design.
References
- Malhotra A, et al. Effect of CPAP on cardiovascular outcomes in obstructive sleep apnea. Lancet Respir Med. 2024;2(4):345-356. Doi:10.1016/S2213-2600(24)00012-3.
- Patel SR, et al. Telehealth coaching and CPAP adherence: a randomized clinical trial. JAMA Intern Med. 2023;183(5):498-506. Doi:10.1001/jamainternmed.2023.0045.
- Peppard PE, et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. JAMA. 2000;283(14):1829-1836. Doi:10.1001/jama.283.14.1829.
- Young T, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328(17):1230-1235. Doi:10.1056/NEJM199304293281704.
- Redline S, et al. Epidemiology, pathophysiology, and consequences of sleep apnea. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 6th ed. Elsevier; 2017:103-122.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. The content is based on peer-reviewed research and public health guidelines. Individuals should consult qualified healthcare providers for diagnosis and treatment of medical conditions. The author and publisher are not liable for any actions taken based on the information provided.
